Dupilumab Benefits Adolescents With Moderate-to-severe Eczema

by Ramya Rachamanti on  October 14, 2019 at 5:19 PM Clinical Trials News
RSS Email Print This Page Comment bookmark
Font : A-A+

Adolescents with moderate-to-severe atopic dermatitis or eczema could benefit from Dupilumab, according to results of a phase IIa open-label trial and a subsequent phase III open-label extension trial.
Dupilumab Benefits Adolescents With Moderate-to-severe Eczema
Dupilumab Benefits Adolescents With Moderate-to-severe Eczema

The results from these latest studies, which are reported in the British Journal of Dermatology, demonstrate the long-term safety and efficacy of the medication for up to 52 weeks of treatment.

Show Full Article


Dupilumab works by stopping the action of certain substances in the body that cause the symptoms of eczema. Specifically, it is a monoclonal antibody against interleukin-4 receptor alpha.

"Adolescents with moderate-to-severe atopic dermatitis have a high disease burden that negatively affects quality of life, and patients are in need of therapies that can be used long-term," said senior author Ashish Bansal, MD, of Regeneron Pharmaceuticals, Inc., in Tarrytown, New York.

"Results from these trials show that dupilumab provides substantial and sustained clinical benefit to these patients with an acceptable safety profile."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive